Concepedia

Paul Kershaw

PK

Statistics

Publications

9

Citations

1.5K

H-Index

9

Active since

2000

Affiliations

Johnson & Johnson (United States)(Current)

Janssen (United States)

Janssen (Belgium)

Paul Kershaw is an author at Johnson & Johnson (United States) specializing in medicine, cognitive impairment, and dementia.

Publications per year

2000–2007

9

Publications

9

A 5-month, randomized, placebo-controlled trial of galantamine in AD

Pierre N. Tariot, Paul R. Solomon, Julie Morris et al. · Neurology · 2000 · 923 citations

, , +16

Reduction of Behavioral Disturbances and Caregiver Distress by Galantamine in Patients With Alzheimer’s Disease

Jeffrey L. Cummings, Lon S. Schneider, Pierre N. Tariot et al. · American Journal of Psychiatry · 2004 · 181 citations

, , +17

The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months

Murray A. Raskind, Elaine R. Peskind, Luc Truyen et al. · Archives of Neurology · 2004 · 168 citations

, , +17

Galantamine Maintains Ability to Perform Activities of Daily Living in Patients with Alzheimer's Disease

Douglas Galasko, Paul Kershaw, Lon S. Schneider et al. · Journal of the American Geriatrics Society · 2004 · 67 citations

, , +17

Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease

Constantine G. Lyketsos, William E. Reichman, Paul Kershaw et al. · American Journal of Geriatric Psychiatry · 2004 · 44 citations

, , +13

1–5 of 9